Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company 2023-01-03 16:00
Everest Medicines to Hold New Corporate Strategy Online Conference Calls 2022-12-30 08:05
Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy 2022-12-30 08:00
Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma 2022-12-28 08:00
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis 2022-12-22 08:00
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone 2022-12-15 08:00
Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy 2022-11-28 08:27
Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy 2022-11-15 08:00
Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults 2022-10-19 20:15
Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections 2022-10-08 08:00
Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases 2022-09-26 08:00
Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth 2022-09-19 08:00
Everest Medicines Announces the Departure of CEO, Kerry Blanchard 2022-08-26 07:30
Everest Medicines Announces Interim Results for First Half of 2022 2022-08-24 21:10
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories 2022-08-16 07:15
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan 2022-08-11 08:00
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics 2022-07-18 08:00
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics 2022-07-18 08:00
Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer 2022-06-10 11:12
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients 2022-06-04 20:30
1 2 3 4 5 6 7